Trial Profile

A phase 1, prospective study to compare safety, tolerability, biodistribution and pharmacokinetics of a single dose of 89Zr-DFO- girentuximab with the antibody produced by ADRM-free adapted cell lines or original cell lines in patients with indeterminate renal masses

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Mar 2024 Status changed from active, no longer recruiting to completed.
11 Mar 2024 Status changed from recruiting to active, no longer recruiting.
13 Nov 2023 Recruitment completion is expected on 26 Mar 2024, according to ISRCTN: Current Controlled Trials.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com